Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 1 of 47
`
`
`
`
`
`
`
`
`Curriculum vitae
`
`
`
`Geoffrey Hale
`
`
`
`
`
`
`
`
`
`
`
`
`1 of 47
`
`BI Exhibit 1003A
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`British
`
`64 Arlington Drive, Marston, Oxford, OX3 0SJ.
`+44 1865 248260
`
`
`
`
`geoff@geoff-hale.com
`
`
`
`Fitzwilliam College, University of Cambridge
`
`BA degree course: Natural Sciences
`
`
`
`PhD: Department of Biochemistry, Cambridge.
`
`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 2 of 47
`
`29 Jun 2017
`
`Freelance Scientist and Consultant
`Managing Director, Bioarchitech
`Chair of board of directors, The Native Antigen Company
`Non-executive director, Absolute Antibody
`
`2nd September 1953
`
`Date of completion
`
`Current posts
`
`
`
`
`
`
`
`
`
`
`
`
`Date of Birth
`
`Nationality
`
`Address
`Tel
`
`
`
`Email
`
`University
`
`Undergraduate
`
` 1971-1972 Biology of cells, Chemistry, Physics, Maths Class 1
` 1972-1973 Biochemistry, Chemistry, Exp. Psychology
`Class 1
` 1973-1974 Biochemistry
`
`
`
`Class 2.1
`
`Awards
`
` 1972-1973 Exhibition
` 1973-1974 Scholarship
` 1972, 1973 Examination prizes
`
`Postgraduate
`
` 1974-1977 Supervisor Prof. R.N. Perham
`
`Thesis "Structure of the pyruvate dehydrogenase complex of E. coli."
`
`Academic Career
`
` 1977-1980 Research Assistant, Department of Biochemistry, Cambridge.
`
`Employed on an SRC project grant, I continued my studies on the structure and function
`of the pyruvate dehydrogenase complex, using a wide range of protein chemical and
`physical biochemical techniques.
`
` 1980-1984 Research Assistant, Department of Pathology, Cambridge.
` 1985-1986 Research Associate, Department of Pathology, Cambridge.
` 1986-1995 Senior Research Associate, Department of Pathology, Cambridge
`
`During this time I worked with Prof. H. Waldmann on therapeutic monoclonal antibodies,
`funded first by an MRC project grant, then by MRC programme grants and the Kay
`Kendall Research Fund. We identified a wide range of antibodies against human
`
`2 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 3 of 47
`
`leukocytes, defined rules for using them to clear target cells and used many of them in
`clinical trials of immunosuppression and tumour therapy.
`
` 1989-1995 Administrative payment and merit award.
` 1990-1995 Manager, Therapeutic Antibody Centre, Regional Blood Transfusion Centre,
`Cambridge.
`
` I
`
` set up a group with five staff to produce pilot scale quantities of monoclonal antibodies
`for the clinical trials according to appropriate quality guidelines. I designed and supervised
`the construction of a clean room facility and was responsible for overall supervision of the
`antibody production as well as development of new techniques. In addition, I maintained
`regular liaison with a large number of clinical teams using the antibodies for trials.
`
` 1995-1998 Research Lecturer, Dunn School of Pathology, Oxford.
` 1998-2000 Reader in Therapeutic Immunology, Dunn School of Pathology, Oxford
` 2000-2007 Professor of Therapeutic Immunology, Dunn School of Pathology, Oxford
` 1995-2007 Research Director, Therapeutic Antibody Centre, Oxford
` 2004-now Qualified Person, recognised by MHRA for release of Investigational
`
`
`Medicinal Products.
` 2007-2016 Visiting Professor of Therapeutic Immunology, Dunn School of Pathology,
`
`
`Oxford
`
`
`During 1994-5 I designed and supervised the construction of a new purpose-built GMP
`facility for pilot production of therapeutic biologicals. I established a team of 8-9 staff,
`training them in good manufacturing practice and continuing antibody production and
`clinical liaison. We brought more than 25 new therapeutic antibodies to the clinic involving
`trials in more than 5000 patients.We worked closely with numerous Biotech companies to
`help in the commercial development of several projects. In 2001, Campath was approved
`by the FDA and EMEA for treatment of chronic lymphocytic leukaemia. Other antibodies,
`including CD4 and CD3 are currently in commercial development for induction of tolerance
`to protein therapeutics and treatment of autoimmune diseases. In June 2004, the TAC
`received a Manufacturer's Authorisation from the Medicines and Healthcare Products
`Regulatory Agency (MHRA), one of the first following the introduction of this scheme in
`May 2004. It has now changed focus to work on vaccines and gene-therapy products.
`
`Commercial Career
`
` 2002-2004 Founder and Consultant, BioAnaLab Limited
` 2004-2010 Chief Executive Officer/Managing Director, BioAnaLab Limited
` 2010-2011 Chief Scientist, Millipore BioPharma Services, Merck Millipore
`
` I
`
` founded BioAnaLab as a spin-out based on the bioanalytical techniques developed at the
`TAC. The Company provides contract analytical services to the pharmaceutical industry
`and specialises in the analysis of biologics such as antibodies, vaccines, growth factors
`and cytokines. Technologies include ELISA, flow cytometry and surface plasmon
`resonance, and are applied to batch release, formulation, pharmacokinetics and
`immunogenicity studies in the course of pre-clinical and clinical trials. The company grew
`to employ 50 staff by 2009 when it was acquired by Millipore Corporation. I continued to
`manage the company through the integration and subsequent acquisition of Millipore by
`Merck KGaA.
`
`3 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 4 of 47
`
`
` 2011-now Chairman of the board of directors, The Native Antigen Company Limited
` 2011-now Sole Trader, Geoff Hale Developments
` 2012-now Director, Absolute Antibody Limited
` 2013-2015 CEO and Director, Mablyte Limited
` 2015-now Managing Director, Bioarchitech Ltd
`
` I
`
` am a founder, investor and board director of a number of biotechnology companies with
`interests in infectious disease, immunology, biological manufacture and testing and
`oncology.
`
`Teaching
`
` 1974-1980 Supervisor for Fitzwilliam College in Biology of Cells and Biochemistry.
`
`
`Assistant demonstrator in practical classes for Biochemistry.
` 1980
`Tutor for St. Andrew's Tutorial College, Cambridge.
` 1980-1995 Assistant demonstrator in practical classes in Pathology.
`
`
`Supervisor of numerous Part 2 research project students.
`
`
`Supervisor of Immunology option (Part 2 Pathology)
`
`
`Assistant lecturer in Pathology.
` 1981-2004 Supervisor of several trainee technicians (from Youth Training scheme to
`
`
`Higher National Diploma).
` 1984-1996 Supervisor of three PhD students.
` 1993-2013 Supervisor of numerous short-term work experience students
` 1996-2002 Occasional lecturer on various immunology courses (Oxford, London,
`
`
`Cranfield Universities)
` 1997-2002 Lecturer in Biochemistry (Biotechnology option course)
` 2000-now Lecturer in Pathology (Immunology FHS option course)
` 2006-2011 Member of curriculum advisory committee, Brookes University
` 2013-now Lecturer in Biochemistry
`
`Although teaching has not been my main job, I have enjoyed a wide variety of teaching
`experience; lecturing to large groups, conducting small tutorial classes, and demonstrating
`practical techiques to classes and individuals.
`
`Publications
`
` 1977-1992 Co-author of 17 original articles and one meeting abstract about the
`structure and function of pyruvate dehydrogenase - see enclosed list.
` 1982-now Author or co-author of >390 reviews, original articles and meeting abstracts
`connected with therapeutic uses of monoclonal antibodies - see enclosed list.
`
`
`In addition to publications, the nature of my work in the TAC and at BioAnaLab
`necessitated the writing of a large number of formal documents, including standard
`operating procedures, annual reports, commercial contracts, reports of clinical trials etc.
`
`
`4 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 5 of 47
`
`Professional Societies
`
`British Society for Immunology.
` 1981
` 1992-2004 International Society for Hematotherapy and Graft Engineering.
` 1997-2001 European Society for Animal Cell Technology
` 1998-2000 British Association for the Advancement of Science
` 1998-2000 American Association for the Advancement of Science
` 2004-2011 American Association for Pharmaceutical Sciences
`
`
`Committee Membership
`
` 2006-2012 NC3Rs/ABPI Biologicals Expert Working Group
`
`Invited lectures
`
` 1984
`
`
`
`
` 1986
`
`
` 1987
`
`
` 1988
`
`
`
`
`
`
`
`
`
`
`
`
` 1989
` 1990
`
`
`
`
`
`
` 1991
` 1992
` 1993
`
`
`
`
`
`
`
`
`
`
`
`
`1994
`1995
`1996
`1997
`
`
`
`
`1998
`
`Royal College of Pathologists symposium on Developments in
`Bone Marrow Transplantation. London.
`LRF workshop on Bone Marrow Transplantation. London.
`12th Annual meeting of the European Cooperative group for Bone Marrow
`Transplantation. Courmayeur.
`4th International symposium on therapy for acute Leukemias, Rome.
`Lymphokines in Haemopoiesis. London
`Special Leukaemia Review - East Anglia IMLS. Cambridge
`Clinical Use of Monoclonal antibodies. Amsterdam.
`
`14th Annual meeting of the European Cooperative Group for Bone Marrow
`Transplantation. Chamonix.
`Paediatric Bone Marrow Transplantation meeting. Manchester.
`British Council course on Bone Marrow Transplantation. London.
`Leukaemia 1988 - recent progress in Biology and Clinical Research. Genoa.
`Scientific symposium - American society for Haematology, Atlanta, USA
`Satellite symposium on Non-Hodgkin's lymphoma, British Society of
`Haematology. Cambridge.
`Cancer and the Immune System, Venice
`From Clone to Clinic, Amsterdam
`Immunotherapy with monoclonal antibodies, British Council, Cambridge.
`Cell culture for clinic and pharmaceutical industry, Utrecht
`Labelling, Quality Control and Clinical Efficacy of Monoclonal Antibodies for
`Scintigraphy, IAEA Symposium Cambridge.
`New approaches for treating haematological malignancy, LRF International
`Symposium, London.
`Advances in Clinical Immunology, Royal College of Physicians, Edinburgh.
`Northern Bone Marrow Transplant Group Symposium, Leeds.
`Multiple Sclerosis Grantholders meeting, London.
`Antibody-based Therapeutics, IBC, Washington, USA.
`Biochemical Society Symposium, Manchester.
`Royal Society of Medicine/Transplantation Society joint symposium, London.
`European Biotechnology Symposium, Edinburgh.
`Biosym 97, Boston (Keynote Speaker).
`American Society for Haematology, LeukoSite/Ilex CLL meeting, San Diego.
`International Marrow Transplant Registry Annual Meeting, Keystone.
`
`
`
`5 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 6 of 47
`
`
`
`
`
`
`
`1999
`
`
`
`
`2000
`
`
`
`
`2001
`
`
`
`
`
`
`
`
`2002
`2003
`
`
`
`
`
`
`
`
`2004
`
`
`
`
`
`
`
`
`
`
`2005
`
`
`
`
`
`
`
`
`
`
`2006
`
`
`
`
`
`
`
`
`2007
`
`
`
`
`
`
`
`
`
`
`2008
`
`
`
`
`
`
`2009
`
`
`
`
`
`Haemopoietic Stem Cell Symposium, Birmingham (The George Bird
`Memorial Lecture)
`Bone Marrow Transplantation in Childhood, Manchester.
`European Society for Haemopheresis, Malmo (tribute to Dr Martin
`Lockwood)
`Royal College of Medicine, London
`International Society for Hematotherapy & Graft Engineering, San Diego.
`CAMPATH-1H International Advisory Board Meetings, Kloster Irsee and
`Cape Cod
`IBMTR/ABMT Tandem BMT meeting, Keystone
`MBI bioprocessing course, London
`UBS Warburg Investors meeting, London
`CAMPATH-1H International Advisory Boad Meeting, Berlin
`Campath in CLL, Royal Soc. Medicine, London
`Massachusetts Biotech Meeting, Boston
`New Horizons in Antibody Induction Therapy, Northwestern University,
`Chicago
`Third International Congress on Monoclonal Antibodies in Cancer, Quebec
`Biologics Safety, Vision in Business, London
`
`Immunogenicity of Protein-based Therapeutics, IIR, Amsterdam
`Bioval 2004, Royal Pharmaceutical Society
`Mabs in bone marrow transplantation, Marbella
`American Transplant Congress, Boston
`Immunogenicity of Protein-based Therapeutics, IIR, London
`PABORD, London
`Protein Immunogenicity, Barnett, Brussels
`Recombinant Antibodies, IBC, Berlin
`National Biotechnology Congress, San Francisco
`Comparability and Immunogenicity, IBC, Vienna
`Tolerance Symposium, Newcastle
`Immunogenicity, Barnett, Philadelphia
`TEDA Bioform, Tianjin, China
`Cell Biology Symposium, Brookes University, Oxford
`UK CLL forum, London
`SCI Pharm, Edinburgh
`Comparability and Immunogenicity, IBC, Zurich
`BA Festival of Science, Norwich
`Immunogenicity Workshop, Bioveris, Oxford
`Predicting adverse reactions to biologics, British Toxicology Society,
` Guildford
`Comparability and Immunogenicity, Informa, Berlin
`BIAcore users meeting, Dublin
`EMEA immunogenicity workshop, London
`Royal Society of Chemistry, Newmarket
`Lymphoma Forum, Chester
`DIA/AAPS Immunogenicity workshop, Bethesda
`EBF Forum, Barcelona
`Oxford Innovation Society, Oxford
`Reid Bioanalytical Forum, Guildford
`QI Immunogenicity Meeting, Baltimore, USA
`
`6 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 7 of 47
`
`AHPPI winter meeting, London
`Biomarkers Congress, Manchester
`Gyros Users Meeting, Uppsala
`EBF Forum, Barcelona
`Research Gala, Birmingham University
`Joint Conference of European Pharmacological Societies, Berlin
`Hanson Wade Immunogenicity Conference, Frankfurt
`Visiongain Biosimilars Conference, London
`Isis Angels Network, Oxford
`VentureFest, Oxford
`6th Annual Biologics Symposium, London
`Science Festival, Cambridge
`EUFEMED, London
`BioProcess International, Boston
`
`
`2010
`
`
`
`
`
`
`2011
`
`
`
`
`
`
`2012
`2013
`2016
`
`
`2017
`
`
`
`
`
`Besides these invited plenary lectures at public meetings, I have participated in many
`other conferences and given seminars at numerous research institutions in the UK and
`abroad. Abstracts or proceedings of some of these meetings are included in the reference
`list.
`
`Meetings organised and/or chaired
`
` 1984- 2000 I organised an annual "CAMPATH users" meeting for evaluation and
`
`
`discussion of clinical results. I was responsible for collecting data, analysis,
`
`
`registration of participants, co-chairing and presentation of data.
` 1986
`Third Leukocyte Workshop Oxford - chair of one session
` 1991
`Deputy Director of British Council Course "Immunotherapy with monoclonal
`
`
`antibodies", Cambridge.
` 1993
`European Group for Bone Marrow Transplantation, Garmisch
`
`
`- chair of one session.
` 1998
`Radiolabelled antibodies users meeting, Oxford
` 2000
`Future Trends in Therapeutic Antibodies, London
` 2001
`Mab Seminar, Amersham-Pharmacia, London
` 2002
`Radiolabelled antibodies users meeting, Oxford
`
` 2003
`Biologics Safety, Vision in Business, London (workshop)
`
`
`Immunogenicity of Protein-based Therapeutics, IIR, Amsterdam (workshop)
` 2004
`Immunogenicity of Protein-based Therapeutics, IIR, London (workshop)
` 2005
`Immunogenicity of Protein-based Therapeutics, IBC, Vienna (workshop)
`
`
`Recombinant Antibodies, IBC, Berlin (chair)
` 2006
`Immunogenicity of Protein-based Therapeutics, IBC, Zurich (workshop)
` 2007
`Predicting adverse reactions to biologics, BTS, Guildford (chair)
` 2007
`Comparability of biologics, IBC, Berlin (workshop)
` 2010
`Biomarkers symposium, Oxford
` 2011
`Biosimilars conference, London
` 2015
`Proteins and Antibodies Congress, London
` 2015
`6th Annual Biologics Symposium, London
`
`
`
`7 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 8 of 47
`
`Third Leukocyte Workshop, Oxford
`Fourth Leukocyte Workshop, Vienna
`European Commission workshop on Safety and Efficacy of
`Monoclonal antibodies, Paris.
`Sixth Leukocyte Workshop, Kyoto
`
`Participation in International workshops
`
` 1986
` 1989
` 1992
`
`
` 1996
`
`
`Training courses attended
`
`In addition to the conferences and workshops listed above, I have attended the following
`training courses:
`
`1999 Biomarkers and surrogate endpoints: NIH FDA, Bethesda
`
`Registration of Pharmaceuticals in Europe, IBC, Amsterdam
`2000 European GMP legislation and guidelines, Pharmaceutical Quality Group, London
`2002 ISO9000 Awareness - in house course
`
`Non-commercially sponsored clinical trials and the NHS: MCA, Birmingham
`
`Clinical Trials Directive: MCA, London
`
`Fire Safety Training - in house course
`
`First Aid Training - in house course
`
`Antibody Production and Downstream Processing, IBC, London
`
`Characterisation, comparability and regulatory requirements, IBC, London
`2003 WHO Basic GMP Training course for inspectors - in house course
`2004 QP training course on Investigational Medicinal Products, David Begg, York
`2006 GLP for study directors and study personnel - in house course
`2010 FDA cGMP laboratory compliance training – in house course
`
`
`Journals
`
` I
`
` review papers for "Bone Marrow Transplantation", "Transplantation", "Immunology",
`"Clinical and Experimental Immunology", "Journal of Immunological Methods", "Blood" and
`other journals.
`
`Grant reviews
`
` I
`
` frequently review grant applications for the Leukaemia Research Fund, and other
`organisations.
`
`
`Media contacts
`
`Both in Cambridge and Oxford I have taken part in several presentations of our work in
`the media, including interviews on radio and TV, writing press releases and answering
`questions from the press.
`
`
`8 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 9 of 47
`
`Public understanding of science
`
`Spoken at schools, entertained teachers and pupils at the TAC and BioAnaLab and
`prepared a poster presentation for a schools open day.
`
`Prepared a brochure describing the development of therapeutic antibodies and the
`objectives of the TAC which has been widely distributed to students, scientists,
`physicians, industry etc and is also available on the internet.
`
`On the register of the Media Resource Service to provide expertise on monoclonal
`antibody therapy.
`
`Made poster presentations at meetings of the Royal Institution and the Medical Research
`Council 25th anniversary of monoclonal meetings.
`
`Hosted students for work experience from Wychwood School, Oxford, King Alfred's
`School, Wantage and several others.
`
`Research Activities
`
`
`Research interests:
`
`Therapy with monoclonal antibodies.
`
`Fc related functions of rat and human immunoglobulins.
`
`Differentiation antigens of human leucocytes.
`
`Structure and function of GPI-membrane anchors.
`
`Role of CAMPATH-1 antigen in immune and reproductive systems.
`
`Large scale culture and purification of therapeutic proteins.
`
`Quality control methods for therapeutic antibodies.
`
`Allogeneic bone marrow and blood stem cell transplantation.
`
`Serotherapy of leukaemia and lymphoma.
`
`Use of antibodies as immunosuppressants in treatment of autoimmune disease.
`
`Pharmacokinetics and pharmacodynamics of biologicals
`
`Immunogenicity of biologicals
`
`Immune responses to polyethyleneglycol
`
`Oncolytic viruses
`
`
`Collaborations
`
`My work has involved collaboration with many scientists both within the University and
`outside. I have regular contact with clinicians worldwide, who are working on trials of
`monoclonal antibodies particularly in the areas of Haematology, Neurology,
`Rheumatology, Diabetology. Over the years I have collaborated with scientists and
`clinicians at about 150 institutions worldwide.
`
`With Prof. Waldmann, I established a worldwide network of 'CAMPATH users'; this
`consisted of about 50 teams using our antibodies in trials of bone marrow transplantation
`and other clinical treatments. I organised an annual meeting of these teams in Cambridge
`at which we exchanged information and ideas in an informal setting. These meetings have
`been popular and very helpful to our work.
`
`
`
`
`9 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 10 of 47
`
`I have supplied antibodies to many other researchers throughout the world to assist in
`their studies.
`
`
`
`10 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 11 of 47
`
`Amount
`31,055
`2,400
`35,339
`1,270,765
`59,800
`3,399
`144,658
`3,968,712
`100,000
`93,839
`1,341,934
`200,000
`667,000
`752,908
`20,000
`115,494
`61,951
`69,994
`50,000
`
`Research grants:
`
`
`Funder
`Year
`1980-1983 Medical Research Council
`1984-1985 National Kidney Research Foundation
`1989-1992
`Leukaemia Research Fund
`1990-1995 Medical Research Council and the Wellcome Foundation
`1993-1995 Medical Research Council and the Wellcome Foundation
`1994
`Therexsys Ltd
`1994-1998
`BBSRC
`1994-2000 Medical Research Council and LeukoSite Inc
`1996
`LeukoSite Inc
`1997-1999 NHS R&D and LeukoSite Inc
`2000-2002 Millennium Pharmaceuticals Inc
`2000-2002 Millennium Pharmaceuticals Inc
`2001-2004
`SRIF
`2002-2004
`TolerRx Inc
`2002-2003 GlycArt Biotechnology AG
`2003-2004
`Immune Tolerance Network
`2003-2004 Cancer Research UK
`2003-2004 GlycArt Biotechnology AG
`2004-2005 Cancer Research UK
`
`
`
`PhD students
`
`1984-1987 Carol Bindon, "Complement-mediated lysis by monoclonal antibodies for
`
`
`therapy". (MRC and Emmanuel College)
`1988-1992 Meng-Qi Xia, "Characterization and structural analysis of CAMPATH-1
`
`
`antigen" (Churchill College and ORS)
`1992-1995 Vanessa Taylor, "Function of CAMPATH-1 antigen"
`
`
`(MRC collaborative award with The Wellcome Foundation)
`
`
`Patent applications
`
` I
`
` have several granted patents on the subjects of therapeutic applications of CD52
`antibodies and applications of the CAMPATH-1 antigen - see the list at the end.
`
`General contributions (academic)
`
`Department: From 1982 to 1995 I served on the Department Safety Committe as
`representative of the Immunology Division and helped to implement safety policy within
`our Division. I was also a member of the Regional Transfusion Centre Safety Committee.
`
`From 1981 to 1994 I was the local User representative for the University Computing
`Service and help to advise and asssist users in Immunology and Virology New Site.
`
`11 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 12 of 47
`
`
`From 1995 to 2004 I was the Safety Representative for the Therapeutic Antibody Centre,
`responsible for all day-to-day health and safety issues.
`
`From time to time I served on Departmental teaching committees, with appointment of
`PhD students or technicians and with a variety of administrative responsibilities, especially
`when Prof Waldmann was on sabbatical leave and following his move to Oxford.
`
`General contributions (commercial)
`
` I
`
` have helped to liase with commercial organisations to market our antibodies for various
`purposes.
`
`Serotec Ltd (Bicester, Oxford) market a range of our rat antibodies for scientific research. I
`have been instrumental in the transfer of these reagents and providing appropriate
`documentation.
`
`Campath has been developed by many companies over the years: Wellcome Biotech,
`Leukosite Inc, ILEX Oncology, Millennium Pharmaceuticals, Schering AG and Genzyme. I
`have worked with all of them to transfer technology, to assist with regulatory submissions
`to FDA and EMEA and to carry out analytical tests in the course of their clinical trials. In
`2001, this led to the approval of Campath for treatment of CLL by the FDA and EMEA,
`and I have continued to work with the companies since then.
`
`Cantab Pharmaceuticals Ltd (Cambridge) developed our CD45 antibodies for purging
`kidney grafts to reduce rejection. I cooperated with their patent application to protect this
`work. I occasionally acted as a part-time consultant for this company. The CD45 project
`has now been terminated.
`
` I
`
` formed a major collaboration with LeukoSite Inc (Boston, USA) who licensed Campath
`and other therapeutic monoclonal antibodies from our group. They made a substantial
`financial contribution to the new TAC in Oxford and we worked for many years on several
`projects of mutual interest. In 1999 LeukoSite was acquired by Millennium
`Pharmaceuticals and I continued to collaborate with them until they eventually sold their
`interests in therapeutic antibodies in 2002.
`
`In 2000, together with Herman Waldmann and Steve Cobbold, I became one of the
`scientific founders of TolerRx Inc (Cambridge, USA) a start-up biotech company devoted
`to development of antibodies for inducing tolerance to proteins and tissues. TolerRx has
`taken up licenses to various antibodies worked on at the Therapeutic Antibody Centre and
`was a major sponsor of our research.
`
`In 2002 I started a collaboration with GlyArt Biotechnology AG (now part of Roche) to
`improve the effector functions of antibodies. This project was important to the company in
`developing proof of principle for their technology and supporting their case for investment.
`
`In October 2002, together with Peppy Rebello and Steve Cobbold, I founded a new Oxford
`University spin-out, BioAnaLab, to provide bioanalytical services to the pharmaceutical
`industry and to develop the diagnostics needed for making antibody therapy more
`effective. We raised an initial investment of £550,000. In September 2004 I took
`
`12 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 13 of 47
`
`responsibility as the Chief Executive Officer, raised further investment of £450,000 and
`returned a net profit from the following year. In 2009 the company was sold to Millipore
`Coporation for a sum in excess of £7.5M.
`
`Since 2010, I have also developed a number of other commercial and charitable interests,
`including chairing the board of a new start-up company, The Native Antigen Company
`which specialises in producing intact viral and bacterial antigens for the diagnostics
`industry.
`
`In 2015, I co-founded a company, Bioarchitech, which is developing a novel oncolytic
`virus.
`
`Consultancies
`
` I
`
` have acted in a private capacity as retained consultant for the following organisations.
`
`
`Cantab Pharmaceuticals Ltd
` 1993
` 1996-1999 LeukoSite Inc
` 1999-2001 Millennium Pharmaceuticals Inc
` 2000-2004 TolerRx Inc
` 2002-2004 BioAnaLab Ltd
` 2011-2012 Lonza Ltd
` 2012-2014 Millipore (UK) Ltd and Eurofins Ltd
` 2012-2016 Cancer Research UK
`
` I
`
` have carried out numerous other ad hoc consultancies for various pharmaceutical
`companies and venture capital organisations and advised various patent attorneys or
`acted as expert witness in connection with court cases.
`
`Other
`
` 1977-1985 Youth club leader, St. Matthew's Church, Cambridge.
` 1984-1989 Churchwarden, St. Matthew's Church (responsible for buildings and
`
`
`administration).
` 1988-1989 Parent governor, Brunswick Nursery School, Cambridge.
` 1989-1995 Co-editor, "Streetwise" community magazine.
` 1994
`Organiser, "Remember, remember", a week-long interactive exhibition of
`
`
`local history, St. Matthew's parish, Cambridge.
` 1995-2000 Occasional assistant helper or leader, Cub scouts Marston, youth club and
`
`
`Sunday School, St Nicholas' Church, Marston.
` 1996-2007 Member, St Nicholas' Parochial Church Council
` 2011-now
` 1998-now Organiser and Leader, annual children's holiday club
` 2000-2007 Churchwarden, St Nicholas' Church, Marston
` 2011-2017
` 2000-2008 Company Director, Marston Church Properties
` 2011-2017
` 2001-2009 Company Director, Divya Shanthi Mission Support
` 2011-now Trustee, Hale Family Charitable Trust
` 2014-now Volunteer assistant, Old Marston Library
`
`13 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 14 of 47
`
` 2015-now Honorary Secretary, Churches Together in Marston and Northway
` 2017-now Treasurer, St Nicholas' Parochial Church Council
`
`Through these activities, and several others, I am interested in promoting the work of the
`Church in the local community.
`
`
`14 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 15 of 47
`
`Publications
`
`Since 1977 I have co-authored more than 400 reviews, original articles and meeting
`abstracts.
`
`Structure and function of pyruvate dehydrogenase
`
`From 1974 to 1980 I worked on the E coli pyruvate dehydrogenase multienzyme complex.
`At that time it was one of the most complex enzymes known, having a molecular weight of
`about 7 million, with three different types of polypeptide chains arranged with octahedral
`(24-fold) symmetry. We used a wide variety of techniques from protein chemistry, physical
`biochemistry and enzymology to dissect some of the relationships between structure and
`function.
`
`Original articles
`
` 1
`
`2
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`Bates, D.L., Danson, M.J., Hale, G., Hooper, E.A., & Perham, R.N. (1977) Self-
`assembly and catalytic activity of the pyruvate dehydrogenase multienzyme
`complex of Escherichia coli. Nature 268, 313-316
`Hale, G. (1977) Structure of the pyruvate dehydrogenase complex of E. coli. PhD
`thesis, Cambridge.
`Stevenson, K.J., Hale, G., & Perham, R.N. (1978) Inhibition of pyuvate
`dehydrogenase multienzyme complex from E. coli with mono- and bifunctional
`arsenoxides. Biochemistry 17, 2189-2192
`Danson, M.J., Hale, G., Johnson, P.J., Perham, R.N., Smith, J., & Spragg, P.
`(1979) Molecular weight and symmetry of the pyruvate dehydrogenase complex
`of Escherichia coli. J. Mol. Biol. 129, 603-617.
`Hale, G., & Perham, R.N. (1979) Limited proteolysis of the pyruvate
`dehydrogenase multienzyme complex of Escherichia coli. Eur. J. Biochem. 94,
`119-126
`Hale, G., & Perham, R.N. (1979) Polypeptide chain stoichiometry and lipoic acid
`content of the pyruvate dehydrogenase complex of Escherichia coli. Biochem. J.
`177, 129-136
`Hale, G., & Perham, R.N. (1979) Primary structure of the swinging arms of the
`pyruvate dehydrogenase complex of Escherichia coli. FEBS Lett. 105, 263-266
`Hale, G., Bates, D.L., & Perham, R.N. (1979) Subunit exchange in the pyruvate
`dehydrogenase complex of Escherichia coli. FEBS Lett. 104, 343-346
`Hale, G., Hooper, E.A., & Perham, R.N. (1979) Amidination of pyruvate
`dehydrogenase complex of Escherichia coli under denaturing conditions.
`Biochem. J. 177, 136-137
`Ambrose Griffin, M.C., Danson, M.J., Griffin, W.G., Hale, G., & Perham, R.N.
`(1980) Kinetic analysis of the role of lipoic acid residues in the pyruvate
`dehydrogenase multienzyme complex of Escherichia coli. Biochem. J. 187, 393-
`401
`Hale, G., & Perham, R.N. (1980) Amino acid sequence around lipoic acid
`residues in the pyruvate dehydrogenase multienzyme complex of Escherichia
`coli. Biochem. J. 187, 905-908.
`Berman, J.N., Chen, G-X., Hale, G., & Perham, R.N. (1981) Lipoic acid residues
`in a take-over mechanism for the pyruvate dehydrogenase multienzyme complex
`of Escherichia coli. Biochem. J. 199, 513-520
`
`15 of 47
`
`BI Exhibit 1003A
`
`

`

`Geoffrey Hale, Curriculum Vitae, Jun 2017
`
`
`
`
`
`Page 16 of 47
`
`14
`
`15
`
`16
`
`17
`
`Danson, M.J., Hale, G., & Perham, R.N. (1981) The role of lipoic acid residues in
`the pyruvate dehydrogenase multienzyme complex of Escherichia coli. Biochem.
`J. 199, 505-511
`Hale, G., & Dixon, H.B.F. (1981) The structure of acetyldihydrolipoic acid.
`Biochem. J. 193, 1034-1035
`Packman, L.C., Hale, G., & Perham, R.N. (1984) Repeating functional domains in
`the pyruvate dehydrogenase multienzyme complex of Escherichia coli. EMBO J.
`3, 1315-1319.
`Hale, G., Wallis, N.G. & Perham, R.N. (1992) Interaction of Avidin with the lipoyl
`domains of the pyruvate dehydrogenase multienzyme complec: three dimensional
`location and similarity to biotinyl domains in carboxylases. Proc. Roy. Soc B 248,
`247-253.
`
`
`Meeting abstract
`
`18
`
`Perham, R.N., Hale, G., & Danson, M.J. (1978) The oxidative decarboxylation of
`pyruvate.Hoppe-Seyler's Z. Physiol. Chem. 359, 1133
`
`
`
`Therapeutic monoclonal antibodies
`
`
`
`Since 1980 I have been working with Herman Waldmann to produce and
`characterise monoclonal antibodies for human therapy. In the course of this work
`we have defined rules for successful use of unmodified antibodies which can
`exploit complement or Fc receptors for cell lysis. The main focus of attention has
`been the CAMPATH-1 family of antibodies, which recognise a previously unknown
`lymphocyte antigen. They are unusually lytic with human complement and appear
`to be particularly effective for cell depletion in vivo. I have produced large
`quantities of these antibodies and collaborated with several clinical teams
`throughout the world who carried out trials of their efficacy as
`immunosuppressants in transplantation and for serotherapy of leukaemia and
`lymphoma
`
`
`Reviews
`
`19